Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Meaghan O’Donnell et al, adding:
“Are we overlooking what matters most to women with von Willebrand disease?
Heavy menstrual bleeding (HMB) is the most common and often the most severe bleeding symptom in women with von Willebrand disease (VWD). Yet a review of interventional VWD prophylaxis trials found that menstrual outcomes remain strikingly underrepresented in study design and reporting.
Among 10 eligible clinical trials, only 2 (20%) incorporated menstrual-related inclusion criteria, while 4 (40%) specifically excluded treated menstrual bleeding from bleed eligibility criteria. Although 80% of studies measured annualized bleeding rates, only 40% collected menstrual outcomes, highlighting a disconnect between trial endpoints and the experiences of many patients.
The authors argue that VWD trials have largely adopted outcome measures designed for hemophilia, rather than focusing on female-specific bleeding.
They call for future studies to incorporate menstrual outcomes, improve reporting of women of reproductive age, and ensure clinical trial design better reflects the needs of people living with VWD.”
Title: Menstrual outcomes are frequently overlooked in von Willebrand disease trials
Authors: Meaghan O’Donnell, Claire Kelly, Rezan Abdul Kadir, Roseline D’Oiron, Petra Elfvinge, Gaby Golan, Keith Gomez, Samantha C. Gouw, Laura Quintas, Karin P.M. van Galen, Michelle Lavin

Other posts featuring RPTH Journal on Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics